NO781688L - PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS - Google Patents

PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS

Info

Publication number
NO781688L
NO781688L NO78781688A NO781688A NO781688L NO 781688 L NO781688 L NO 781688L NO 78781688 A NO78781688 A NO 78781688A NO 781688 A NO781688 A NO 781688A NO 781688 L NO781688 L NO 781688L
Authority
NO
Norway
Prior art keywords
tinidazole
solution
nitroimidazole
drug
aqueous solution
Prior art date
Application number
NO78781688A
Other languages
Norwegian (no)
Inventor
Mahdi Bakir Fawzi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO781688L publication Critical patent/NO781688L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

Fremgangsmåte ved fremstilling av farmakologisk aktive midler. Procedure for the production of pharmacologically active agents.

Foreliggende oppfinnelse vedrører farmasøytiske formuleringer og spesielt formuleringer av nitroimidazol-antimi-krobiske midler med forbedrede løselighet-karakteristika. The present invention relates to pharmaceutical formulations and in particular formulations of nitroimidazole antimicrobial agents with improved solubility characteristics.

Nitroimidazol-antimikrobielle droger er en verdifull klasse av middelet som erkarakterisert vedat de har en 5-nitroimidazol-kjerne og er spesielt anvendelige ved behandling av protozo-infeksjoner som trichomoniasis og amoebiasis og også ved behandling av anaerobe bakterie-infeksjoner. Klas-sen innbefatter sådanne forbindelser som tinidazol, metronidazol og nimorazol. Et problem med denne, forbindelses-klassen er deres dårlige løselighet i vandig media som vanskeliggjør formulering av vandige injeserbart komposisjoner. Det er nå funnet en fordelaktig metode for å sblubilisere nitroimidazol-antimikrobielle droger som. gjør det mulig lett å fremstille vandige løsninger egnet for parenteral injeksjon. Sl.ike formuleringer er av spesiell verdi ved systemisk behandling av anerobe bakterie-infeksjoner. Nitroimidazole antimicrobial drugs are a valuable class of agents characterized by having a 5-nitroimidazole nucleus and are particularly useful in the treatment of protozoan infections such as trichomoniasis and amoebiasis and also in the treatment of anaerobic bacterial infections. The class includes such compounds as tinidazole, metronidazole and nimorazole. A problem with this class of compounds is their poor solubility in aqueous media, which makes formulation of aqueous injectable compositions difficult. An advantageous method of slubilizing nitroimidazole antimicrobial drugs has now been found. makes it possible to easily prepare aqueous solutions suitable for parenteral injection. Such formulations are of particular value in the systemic treatment of anaerobic bacterial infections.

Således tilveibringes ifølge oppfinnelsen en farmasøytisk komposisjon som omfatter en nitroimidazol-antimikrobiell droge i blanding med et farmasøytisk fordragelig salt av Thus, according to the invention, a pharmaceutical composition is provided which comprises a nitroimidazole antimicrobial drug in mixture with a pharmaceutically acceptable salt of

en mono- eller di-hydroksybenzosyre eller med en mono- eller di-hydroksybenzyl-alkohol. a mono- or di-hydroxybenzoic acid or with a mono- or di-hydroxybenzyl alcohol.

Den farmasøytiske komposisjonen ifølge oppfinnelsen kan foreligge i form av en steril vandig løsning eller i form av en fast blanding fremstilt ved å blande komponentene eller ved lyofilisering av en steril vandig løsning av komponentene. The pharmaceutical composition according to the invention can be in the form of a sterile aqueous solution or in the form of a solid mixture prepared by mixing the components or by lyophilizing a sterile aqueous solution of the components.

Også andre bestanddeler kan være tilstede, f.eks. en syre eller base kan tilsettes for å nøytralisere oppløsningen Other components may also be present, e.g. an acid or base may be added to neutralize the solution

(om nødvendig) og for å gi en pH i det fysiologisk fordragelige området seg er egnet for en injeserbar formulering. Salter (f.eks. natriumacetat, natriumlactat, natriumsuccinat eller natriumklorid) og andre løsnings-bestanddeler (f.eks. dekstrose eller mannitol) kan også tilsettes for å gjør løsningen isotonisk. (if necessary) and to provide a pH in the physiologically tolerable range suitable for an injectable formulation. Salts (eg sodium acetate, sodium lactate, sodium succinate or sodium chloride) and other solution ingredients (eg dextrose or mannitol) can also be added to make the solution isotonic.

Hvis et salt eller en hydroksybenzosyre benyttes, foretrekkes en di-hydroksybenzosyre, spesielt gentisinsyre (2,5-di-hydroksybenzosyre). Videre egnet er 2,3-, 3,4- og 3,5-dihydroksybenzensyrer og salisylsyre. Det foretrukne salt er ammdniumsaltet, men natriumsaltet er også egnet såvel som salter med organiske baser som L-arginin, meglumin (N-metyl glukamin), etanolamin og cholin. Alternativt kan hydroksybenzosyre anvendes som fri syre og kan nøytrali-seres ved tilsetning av en ekvivalent mengde av den ønskede base for å gi en vandig løsning av salter for tilsetning av nitroimidazol-drogen. If a salt or a hydroxybenzoic acid is used, a dihydroxybenzoic acid, especially gentisic acid (2,5-dihydroxybenzoic acid), is preferred. Also suitable are 2,3-, 3,4- and 3,5-dihydroxybenzene acids and salicylic acid. The preferred salt is the ammonium salt, but the sodium salt is also suitable as well as salts with organic bases such as L-arginine, meglumine (N-methyl glucamine), ethanolamine and choline. Alternatively, hydroxybenzoic acid can be used as the free acid and can be neutralized by adding an equivalent amount of the desired base to give an aqueous solution of salts for addition of the nitroimidazole drug.

En foretrukket hydroksybenzyl-alkohol er gentisyl-alkohol, eller mono- eller dihydorksybenzyl-alkoholer, f.eks. salisyl-alkohol kan også anvendes. Anvendelsen av en hydroksybenzyl-alkohol har den fordel at en base ikke er nødvendig for å A preferred hydroxybenzyl alcohol is gentisyl alcohol, or mono- or dihydroxybenzyl alcohols, e.g. salicylic alcohol can also be used. The use of a hydroxybenzyl alcohol has the advantage that a base is not necessary to

nøytralisere formuleringen.neutralize the formulation.

Mengden av hydroksybenzosyre eller hydroksybenzyl-alkohol som kreves avhenger av den enkelte og den endelige konsentrasjon som er nødvendig for den anvendte nitroimidazol samt typen av den spesielle hydroksybenzysyre eller hydroksybenzyl-alkohol som anvendes. The amount of hydroxybenzoic acid or hydroxybenzyl alcohol required depends on the individual and final concentration required for the nitroimidazole used as well as the type of particular hydroxybenzoic acid or hydroxybenzyl alcohol used.

Det er nå funnet at å fremstille en vandig løsning av tinidazol i en konsentrasjon anvendelig for intravenøs administre-ring, dvs. :.i en konsentrasjon på opptil 50 mg pr. ml, krever en mengde gentisinsyre fra 2 til 4 vekt-deler basert på tinidazol fortrinnsvis ca. 2,8 vekt-deler. For å fremstille en høyere konsentrasjon av tinidazol, mer egnet for intra muskulær injeksjon, dvs. en konsentrasjon opptil 200 mq pr. ml, krever et lavere forhold av gentisinsyre til tinidazol, dvs. en gentisinsyremengde fra 1 til 2 vekt-deler basert på tinidazolet, fortrinnsvis ca. 1,4 vekt-deler. It has now been found that preparing an aqueous solution of tinidazole in a concentration suitable for intravenous administration, i.e. in a concentration of up to 50 mg per ml, requires an amount of gentisic acid from 2 to 4 parts by weight based on tinidazole, preferably approx. 2.8 parts by weight. To produce a higher concentration of tinidazole, more suitable for intramuscular injection, i.e. a concentration up to 200 mq per ml, requires a lower ratio of gentisic acid to tinidazole, i.e. an amount of gentisic acid from 1 to 2 parts by weight based on the tinidazole, preferably approx. 1.4 parts by weight.

Uten solubiliseringsmiddel er tinidazol bare løselig i vann opptil 5 mg pr. ml. Without a solubilizer, tinidazole is only soluble in water up to 5 mg per ml.

I praksis kan en løsning av nitroimidazol-drogen fremstilles ved å sette den til en vandig løsning av saltet av hydroksybenzosyre eller til én løsning av hydroksybenzyl-alkoholen. Blandingen røres inntil nitroimidazolet er oppløst, pH justeres om nødvendig og løsningen sterilfiltreres så ved å bruke en bakterie-tett membran og fylles i steriel beholdere med et passende volum for den tilsiktede anvendelsen av drogen. Således vil for humant bruk som en intravenøs injeserbar formulering beholdere som inneholder 10 ml av en løsning av tinidazol i en konsentrasjon på 50 mg pr. ml være egnet, mens for intramuskulær bruk kunne beholdere som inneholder 4 ml av en løsning av tiniadzol på 200 mg pr. ml anvendes. In practice, a solution of the nitroimidazole drug can be prepared by adding it to an aqueous solution of the salt of hydroxybenzoic acid or to a solution of the hydroxybenzyl alcohol. The mixture is stirred until the nitroimidazole is dissolved, the pH is adjusted if necessary and the solution is then sterile filtered using a bacteria-tight membrane and filled into sterile containers of an appropriate volume for the intended use of the drug. Thus, for human use as an intravenous injectable formulation, containers containing 10 ml of a solution of tinidazole at a concentration of 50 mg per ml would be suitable, while for intramuscular use containers containing 4 ml of a solution of tiniazole at 200 mg per ml are used.

Alternativt kan oppløsningen etter sterilisering lyofiliseres ved fryst-tørking på konvensjonell måte, f.eks. ved ned-kjøling til -40°C og underkaste den frosne løsningen høy-vakuum i 24 timer for å gi et fast produkt. Det kan være ønskelig å lagre produktet i denne formen idet løsningen lett tilbakeføres umiddelbart før bruk ved å bare tilsette det nødvendige volum vann. Alternatively, the solution after sterilization can be lyophilized by freeze-drying in a conventional manner, e.g. by cooling to -40°C and subjecting the frozen solution to high vacuum for 24 hours to give a solid product. It may be desirable to store the product in this form, as the solution is easily returned immediately before use by simply adding the required volume of water.

Liknende formuleringer kan fremstilles ved å bruk andre nitroimidazoldroger, f.eks. vandig injeserbare formuleringer kan fremstilles ved å bruke metronidazol, nimorazol, ornidazol og bamnidazol med gentisinsyre. Similar formulations can be prepared using other nitroimidazole drugs, e.g. aqueous injectable formulations can be prepared using metronidazole, nimorazole, ornidazole and bamnidazole with gentisic acid.

De følgende er eksempler på farmasøytiske komposisjoner ifølge oppfinnelsen. The following are examples of pharmaceutical compositions according to the invention.

EKSEMPEL 1EXAMPLE 1

En intravenøs injeserbar formulering av tinidazol ble fremstilt med følgende sammensetning: An intravenous injectable formulation of tinidazole was prepared with the following composition:

Gentisinsyren ble rørt med halvparten av vann og den for-tynnede ammoniakkløsningen ble tilsatt langsomt inntil alt det faste stoffet var oppløst og den endelig pH i løsningen var 0,25 + 0,2. Langsomt tilsetning er nødvendig for å unngå misfarging av gentisinsyren. Tinidazolet ble så tilsatt og rørt til en klor-løsning oppstod som ble fortynnet med vann for å gi det endelig volumet på 1 liter. Løsningen ble sterilisert ifølge metoden fra British Farmacopoea (1973) ved filtrering gjennom et bakterie-tett filter under asep-tiske betingelser og fylt i sterile glassbeholdere. The gentisic acid was stirred with half of the water and the dilute ammonia solution was added slowly until all the solid had dissolved and the final pH of the solution was 0.25 + 0.2. Slow addition is necessary to avoid discoloration of the gentisic acid. The tinidazole was then added and stirred until a chlorine solution formed which was diluted with water to give the final volume of 1 liter. The solution was sterilized according to the method from the British Pharmacopoeia (1973) by filtering through a bacteria-tight filter under aseptic conditions and filled into sterile glass containers.

EKSEMPEL 2EXAMPLE 2

En intravenøs injeserbar formulering av tinidazol ble fremstilt som beskrevet i eksempel 1 men med følgende sammensetning: An intravenous injectable formulation of tinidazole was prepared as described in Example 1 but with the following composition:

EKSEMPEL 3 - 5 EXAMPLE 3 - 5

Intravenøs injeserbare formuleringer av tinidazol ble frem-.stilt som beskrevet i eksempel 2 bortsatt fra følgende syrer ble brukt i stedet for para-hydroksybenzosyre: Intravenous injectable formulations of tinidazole were prepared as described in Example 2 except that the following acids were used instead of para-hydroxybenzoic acid:

EKSEMPEL 6 EXAMPLE 6

En intravenøs, injeserbar formulering av tinidazol ble fremstilt med følgende sammensetning: An intravenous, injectable formulation of tinidazole was prepared with the following composition:

Natrium-salisylatet ble oppløset i halvparten av vannet og tinidazolet ble tilsatt og rørt hvilket ga en klar løs-ning. Vann ble tilsatt til et sluttvolum på 100 ml og løsningen ble sterilt filtrert i beholdere som beskrevet i eksempel 1. The sodium salicylate was dissolved in half the water and the tinidazole was added and stirred which gave a clear solution. Water was added to a final volume of 100 ml and the solution was sterile filtered into containers as described in example 1.

EKSEMPEL 7 - 11 EXAMPLE 7 - 11

Intravenøs injeserbare formulering av tinidazol ble fremstilt som beskrevet i eksempel 1 unntatt at i stedet for ammoniakk-løsning 1 ble ekvivalente mengder av de følgende baser tilsatt i hvert tilfelle for å nøytralisere gentisinsyren: Intravenous injectable formulation of tinidazole was prepared as described in Example 1 except that instead of ammonia solution 1, equivalent amounts of the following bases were added in each case to neutralize the gentisic acid:

EKSEMPEL 12 EXAMPLE 12

En intravenøs injeserbar formulering av tinidazol ble fremstilt med følgende sammensetning: An intravenous injectable formulation of tinidazole was prepared with the following composition:

Gentisyl-alkoholen ble oppløst i halvparten av vann og tinidazolet ble tilsatt og rørt hvilket ga en klar opp-løsning. Volumet av oppløsningen ble fylt opp til 100 The Gentisyl alcohol was dissolved in half of the water and the tinidazole was added and stirred to give a clear solution. The volume of the solution was made up to 100

ml og løsningen ble steril filtrert inn i glassbeholdere som beskrevet i eksempel 1. ml and the solution was sterile filtered into glass containers as described in example 1.

EKSEMPEL 13EXAMPLE 13

Et intravenøs injeserbar formulering av tinidazol ble fremstilt som beskrevet i eksempel 12 bortsett fra et metahyd-roksybenzyl-alkohol ble brukt i stedet for gentisyl-alkohol. An intravenous injectable formulation of tinidazole was prepared as described in Example 12 except a metahydroxybenzyl alcohol was used instead of gentisyl alcohol.

EKSEMPEL 14EXAMPLE 14

En steril vandig oppløsning av tinidazol og gentisinsyreA sterile aqueous solution of tinidazole and gentisic acid

(4 ml) fremstilt som beskrevet i eksempel 1 ble fryse-tørket over vakuum ved -40°C i 24 timer hvilket ga et gulaktig fast stoff. (4 mL) prepared as described in Example 1 was freeze-dried under vacuum at -40°C for 24 hours to give a yellowish solid.

EKSEMPEL 15EXAMPLE 15

Produktet fra eksempel 14 ble tilbakeført ved tilsetning av vann for injeksjon E.P. til beholderen. Det faste stoffet gikk øyeblikkelig i oppløsning hvilket ga en klar løsning. Volumet av tilsatt vann ble variert hvilket ga løsninger av tinidazol med følgende konsentrasjoner: The product from example 14 was recovered by adding water for injection E.P. to the container. The solid dissolved immediately giving a clear solution. The volume of added water was varied, giving solutions of tinidazole with the following concentrations:

EKSEMPEL 16 EXAMPLE 16

En intramuskulær injeserbar formulering av tinidazol ble fremstilt som beskrevet i eksempel 1 men med følgende sammensetning: An intramuscular injectable formulation of tinidazole was prepared as described in Example 1 but with the following composition:

EKSEMPEL 17 EXAMPLE 17

Én intravenøs injeserbar formulering av metronidazol med følgende sammensetning ble fremstilt ved å bruke frem-gangsmåten fra eksempel 1: One intravenous injectable formulation of metronidazole of the following composition was prepared using the procedure of Example 1:

EKSEMPEL.18 EXAMPLE.18

En intravenøs injeserbar formulering av himorazol med den følgende sammensetning.ble fremstilt ved å bruke fremgangs-måten fra eksempel 1: An intravenous injectable formulation of himorazole of the following composition was prepared using the procedure of Example 1:

EKSEMPEL 19 EXAMPLE 19

En intravenøs injserbar formulering av bamnidazol medAn intravenous injectable formulation of bamnidazole with

den følgende sammensetning ble fremstilt ved å bruke frem-gangsmåten fra eksempel 1: the following composition was prepared using the procedure of Example 1:

EKSEMPEL 20 EXAMPLE 20

En intravenøs injeserbar formulering av ornidazol med den følgende sammensetning ble fremstilt ved å bruke fremgangs-måten fra eksempel 1: An intravenous injectable formulation of ornidazole of the following composition was prepared using the procedure of Example 1:

Claims (9)

1. Fremgangsmåte for fremstilling av en farmasøytisk formulering av en nitroimidazoldroge karakterisert ved at nitroimidazoldrogen behandles med en vandig løsning av et farmasøytisk fordragelig salt av en1. Process for producing a pharmaceutical formulation of a nitroimidazole drug characterized in that the nitroimidazole drug is treated with an aqueous solution of a pharmaceutically acceptable salt of a mono- eller dihydroksy-benzosyre eller en mono- eller dihydroksybenzyl-alkohol, sterilisering og, om ønsket, lyofilisering av den resulterende oppløsning. mono- or dihydroxy-benzoic acid or a mono- or dihydroxybenzyl alcohol, sterilization and, if desired, lyophilization of the resulting solution. 2. Fremgangsmåte Ifølge krav 1 karakterisert ved at man som nitroimidazoldroge anvender tinidazol. 2. Method According to claim 1, characterized in that tinidazole is used as a nitroimidazole drug. 3. Fremgangsmåte ifølge krav 1 karakterisert ved at man som nitromidazoldrog anvender metronidazol, nimorazol, ornidazol eller bamnidazol. 3. Method according to claim 1, characterized in that metronidazole, nimorazole, ornidazole or bamnidazole is used as the nitromidazole drug. 4. Fremgangsmåte ifølge kravene 1-3 karakterisert ved at nitroimidazoldrogen behandles med en vandig løsning av et farmasøytisk fordragelig salt av gentisinsyren. 4. Method according to claims 1-3, characterized in that the nitroimidazole drug is treated with an aqueous solution of a pharmaceutically acceptable salt of gentisic acid. 5. Fremgangsmåte ifølge krav 4 karakterisert ved at det farmasøytisk fordragelige salt er ammoniumsaltet. 5. Method according to claim 4, characterized in that the pharmaceutically acceptable salt is the ammonium salt. 6. Fremgangsmåte ifølge kravene 1-3 karakterisert ved at nitroimidazoldrogen behandles med en vandig løsning av gentisyl-alkohol. 6. Method according to claims 1-3, characterized in that the nitroimidazole drug is treated with an aqueous solution of gentisyl alcohol. 7. Fremgangsmåte for fremstilling av en vandig injeserbar' løsning av tinidazol ifølge krav 2 karakterisert ved at tinidazolet behandles med en vandig, løsning av ammoniumsaltet av gentisinsyre og steriliseres. 7. Process for producing an aqueous injectable solution of tinidazole according to claim 2, characterized in that the tinidazole is treated with an aqueous solution of the ammonium salt of gentisic acid and sterilized. 8. Fremgangsmåte ifølge krav 7 karakterisert ved at tinidazolet anvendes i en konsentrasjon opptil 50 mg pr. ml og gentisinsyren foreligger i en mengde på ca. 2,8 vekt-deler basert på tilstedeværende tinidazol. 8. Method according to claim 7, characterized in that the tinidazole is used in a concentration of up to 50 mg per ml and the gentisic acid is present in an amount of approx. 2.8 parts by weight based on tinidazole present. 9. Fremgangsmåte ifølge krav 7 karakterisert ved at tinidazolet anvendes i en konsentrasjon opptil 200 mg pr. ml og gentisinsyren foreligger i en mengde I på ca. 1,4 vekt-deler basert på det tilstedeværende tinidazol.9. Method according to claim 7, characterized in that the tinidazole is used in a concentration of up to 200 mg per ml and the gentisic acid is present in an amount I of approx. 1.4 parts by weight based on the tinidazole present.
NO78781688A 1977-05-14 1978-05-12 PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS NO781688L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2037977 1977-05-14

Publications (1)

Publication Number Publication Date
NO781688L true NO781688L (en) 1978-11-15

Family

ID=10144988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO78781688A NO781688L (en) 1977-05-14 1978-05-12 PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS

Country Status (16)

Country Link
JP (1) JPS542315A (en)
AU (1) AU504551B1 (en)
BE (1) BE867040A (en)
DE (1) DE2820992A1 (en)
DK (1) DK212678A (en)
ES (1) ES469749A1 (en)
FI (1) FI781507A (en)
FR (1) FR2390162A1 (en)
IL (1) IL54687A0 (en)
IT (1) IT1115599B (en)
LU (1) LU79655A1 (en)
NL (1) NL7805158A (en)
NO (1) NO781688L (en)
PT (1) PT68034B (en)
SE (1) SE7805471L (en)
ZA (1) ZA782736B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070778D1 (en) * 1979-08-11 1985-07-25 Bayer Ag Antimycotic agents with enhanced release of the active ingredients
FR2624736B1 (en) * 1987-12-16 1991-03-22 Dietlin Francois NEW WATER-DISPERSIBLE PHARMACEUTICAL COMPOSITIONS BASED ON ORNIDAZOLE
CN104127379A (en) * 2014-08-14 2014-11-05 珠海亿邦制药股份有限公司 Ornidazole injection and preparation method thereof
CN110538144A (en) * 2019-06-13 2019-12-06 南京瓦尔生物医药有限公司 Ornidazole injection and S-ornidazole injection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition

Also Published As

Publication number Publication date
PT68034A (en) 1978-06-01
JPS542315A (en) 1979-01-09
IT7823351A0 (en) 1978-05-12
NL7805158A (en) 1978-11-16
ZA782736B (en) 1979-05-30
FR2390162A1 (en) 1978-12-08
IT1115599B (en) 1986-02-03
IL54687A0 (en) 1978-07-31
LU79655A1 (en) 1979-12-06
PT68034B (en) 1979-10-24
DK212678A (en) 1978-11-15
DE2820992A1 (en) 1978-12-07
BE867040A (en) 1978-11-13
AU504551B1 (en) 1979-10-18
ES469749A1 (en) 1978-12-16
FI781507A (en) 1978-11-15
SE7805471L (en) 1978-11-15

Similar Documents

Publication Publication Date Title
NO175406B (en) Process of preparing piroxam in aqueous solution
US9265837B1 (en) 5α-androstane-3β,5,6β-triol injection and preparation method therefor
CN105434373B (en) A kind of injection Oxiracetam lyophilized preparation and preparation method thereof
NO781688L (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS
CN105213330A (en) A kind of Parecoxib sodium freeze-dried preparation and preparation method thereof
CN109200023A (en) A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection
CN111346061B (en) Chlorogenic acid composition and preparation method thereof
EP0003682B1 (en) Process for solubilizing an insoluble drug and an aqueous solution prepared by this process
US4889862A (en) Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids
CN113730344B (en) Naproxen preparation for injection and application thereof
DK159376B (en) PROCEDURE FOR THE PREPARATION OF A STABLE, SOLID, WATER SOLUBLE PREPARATION FOR WATER RECONSTITUTION OR Aqueous CARRIER AS A STABLE SOLUTION OF 4 '- (9-ACRIDINYLAMINO) METHAN-SULPHONES
CN101491495B (en) Salvianolic acid B magnesium injection, preparation method and use thereof
CN103877032A (en) Vecuronium bromide pharmaceutical composition for injection and preparation method thereof
CN106913532A (en) A kind of hydrochloride for injection epirubicin and preparation method thereof
US4327084A (en) Aqueous solution for intravenous administration
CN101780084A (en) Injection composition using levo leucovorin or salt thereof as major ingredients
CN103585119A (en) Stabilization preparation containing epoprostenol and medical salt of epoprostenol and preparation method of stabilization preparation
CN103494778B (en) Esomeprazole sodium freeze-dried preparation and preparation method thereof
KR100606621B1 (en) Aqueous ecabet sodium solution preparation
US4416874A (en) Injectable compositions of BBM-928A
JP2019085338A (en) Lyophilized pharmaceutical composition containing bortezomib
AU2018437600B2 (en) Novel pentosan polysulfate sodium preparation
DE2538678A1 (en) Injectable solns. contg. trimethoprim and sulphamethoxazole - of physiologically tolerable pH and contg. only small amts. of organic solvents
US20030139468A1 (en) Amiodarone solutions suitable for intravenous administration
NO890198L (en) STABILIZED DRY PREPARATION OF CYTOSTATIC EFFECTIVE ANTRACYCLIN ANTIBIOTIC AND PROCEDURE FOR PREPARING THIS